Home Cytokines and Immune Cell Markers Natural Killer Cell Function Test: NK Cell Activity, Immune Defense, and Meaning

Natural Killer Cell Function Test: NK Cell Activity, Immune Defense, and Meaning

By
Vita Library
-
4
Learn how natural killer cell function tests measure cytotoxicity, CD107a degranulation, perforin, and immune activity, and why specimen handling and clinical context determine the meaning.

A natural killer cell function test evaluates how well NK cells respond to stimulation or damage target cells in the laboratory. Depending on the method, it may measure target-cell killing, CD107a degranulation, perforin expression, granzyme content, or cytokine production. These tests are used mainly when clinicians suspect an inborn error affecting cytotoxic lymphocytes, natural killer cell deficiency, or hemophagocytic lymphohistiocytosis (HLH), especially in patients with severe herpesvirus infections, unusual papillomavirus disease, recurrent hyperinflammation, or a compatible family history. They are not the same as an NK cell count. A normal number of NK cells can coexist with defective killing, while low bulk activity may simply reflect too few NK cells in the sample. Results are highly sensitive to acute illness, corticosteroids, immunosuppressive treatment, specimen age, temperature, shipping, and laboratory technique. For HLH screening, targeted perforin and CD107a assays are often more informative and reproducible than a traditional general cytotoxicity test. No single functional result establishes a diagnosis; interpretation requires cell counts, clinical features, assay controls, repeat confirmation when appropriate, and sometimes genetic testing.

  • Cytotoxicity assays measure target-cell death, while CD107a assays measure granule release.
  • Perforin and granzyme tests examine parts of the killing machinery rather than complete killing.
  • NK-cell count and NK-cell function answer different questions and can disagree.
  • Fresh, viable cells and tightly controlled transport are essential for reliable results.
  • Abnormal findings should be matched to the suspected disorder and confirmed with focused immune or genetic testing.

Table of Contents

What NK Cell Function Means

Natural killer cells are cytotoxic innate lymphocytes. They survey other cells for combinations of activating and inhibitory signals, then respond when a target appears infected, stressed, or transformed. Their activity is not one single action. It includes recognizing the target, forming an immune synapse, moving cytotoxic granules toward that contact, releasing perforin and granzymes, triggering target-cell death, producing cytokines, and sometimes using antibodies attached to the target through the Fc receptor CD16.

A laboratory can test different steps in this sequence. Traditional NK cytotoxicity measures the final outcome: how many standardized target cells die after incubation with the patient’s effector cells. A CD107a assay evaluates degranulation, a step immediately before or during release of cytotoxic granules. Intracellular staining can show whether perforin, granzyme B, or related proteins are present. Cytokine assays may measure interferon-gamma after stimulation.

These measurements are related but not interchangeable. An NK cell may contain perforin yet fail to release granules. Another cell may degranulate normally but have ineffective granule contents. A bulk killing assay can be low because the sample contains few NK cells, because the cells are intrinsically defective, because the target-cell interaction is impaired, or because the specimen lost viability during transport.

NK function also depends on context. The same cells can respond differently to a tumor-cell line, antibody-coated target, viral stimulus, or cytokine combination. A normal response to one laboratory stimulus does not prove that every antiviral pathway works normally. Likewise, reduced activity in one assay does not automatically predict the patient’s ability to control every infection.

Function in blood is not identical to function in tissues. NK cells inside the liver, uterus, lungs, lymph nodes, or tumors encounter different cytokines and receptor ligands. A blood assay provides a controlled model of selected functions; it does not reproduce the entire immune environment.

The test is therefore best viewed as a mechanistic tool. It helps locate where cytotoxic immunity may be failing and guides more specific testing. It is not a general measure of “immune strength,” vitality, cancer resistance, fertility, or response to supplements.

Types of NK Cell Function Tests

The phrase “NK cell function test” can refer to several methods. The test name, stimulus, target cells, incubation time, and reported endpoint should be checked before interpreting a result.

A direct cytotoxicity assay mixes the patient’s peripheral blood mononuclear cells or purified NK cells with a susceptible target-cell line, commonly K562 cells. Target death may be detected by radioactive chromium release, flow-cytometric viability dyes, apoptosis markers, enzyme release, luminescence, or imaging. Results are often reported at several effector-to-target ratios because killing depends on how many immune cells encounter each target.

A degranulation assay stimulates NK cells with K562 cells or another trigger while an antibody detects CD107a, also called LAMP-1. CD107a normally lines the membrane of cytotoxic granules. When a granule fuses with the cell surface, CD107a becomes externally visible. Flow cytometry measures the percentage of NK cells that mobilize CD107a and sometimes the change in fluorescence intensity.

Perforin and granzyme expression assays stain cytotoxic proteins inside NK cells and often CD8 T cells. These tests can identify absent or markedly reduced perforin expression and help screen for selected genetic HLH disorders. Normal protein quantity does not guarantee normal protein function, granule trafficking, or release.

Additional specialized assays examine SAP, XIAP, Munc13-4, syntaxin-11, Munc18-2, signaling responses, receptor expression, antibody-dependent cellular cytotoxicity, cytokine production, or serial killing. These are ordered for focused questions and may be available only in reference or research laboratories.

Some commercial tests measure interferon-gamma released after proprietary stimulation and label the result “NK cell activity.” Such assays do not directly quantify target-cell killing and should not be assumed equivalent to a cytotoxicity or CD107a test. The report’s method determines what can be concluded.

An NK cell count is a separate flow-cytometry test that enumerates CD3-negative CD16/CD56-positive cells. Expanded phenotyping can identify CD56-bright and CD56-dim subsets or maturation markers, but phenotype alone does not establish functional competence.

How a Cytotoxicity Assay Works

The laboratory first isolates or prepares the patient’s white blood cells. These effector cells are incubated with labeled target cells that are intentionally sensitive to NK-cell attack. K562, a leukemia-derived cell line with weak expression of inhibitory HLA class I signals, is widely used because healthy NK cells usually kill it without prior antigen-specific sensitization.

Several effector-to-target ratios may be tested. For example, more patient effector cells are added in one well and fewer in another. A healthy sample should generally produce more target death as the ratio increases. The laboratory compares the result with reference data, assay controls, and sometimes a simultaneously collected healthy control.

Older assays labeled targets with radioactive chromium. When the target membrane was damaged, chromium entered the surrounding fluid and could be measured. Modern flow-cytometry methods label targets and use dyes or apoptosis markers to distinguish living from dead cells. Each method has different reference intervals and sources of variability, so results from separate laboratories cannot be compared as though they use one universal scale.

Bulk cytotoxicity combines several variables. The mononuclear-cell preparation contains NK cells, T cells, monocytes, and other cells. Short incubation with K562 targets is intended to emphasize innate NK activity, but the number and proportion of NK cells still matter. If a sample contains very few NK cells, total killing may be low even if each remaining NK cell is competent.

Some laboratories calculate or discuss activity relative to the NK-cell percentage. Others purify NK cells, but purification can activate, stress, or selectively lose subsets. There is no single method that eliminates all biological and technical variation.

Target-cell quality also matters. Passage number, viability, culture conditions, labeling, target density, and resistance to spontaneous death affect the assay. Laboratories monitor spontaneous target death and maximum lysis. If controls fail, the patient result should not be interpreted.

A normal cytotoxicity result shows that the tested cells could kill that target under those conditions. It does not exclude every cytotoxic-pathway disorder, especially partial defects, stimulus-specific abnormalities, or disease modified by treatment. An abnormal result should be localized with cell counts, degranulation, protein-expression assays, and genetic analysis rather than treated as a final diagnosis.

CD107a, Perforin, and Related Screening

CD107a degranulation testing is especially important in suspected familial HLH and related granule-release disorders. After stimulation, normal cytotoxic lymphocytes move granules to the immune synapse and fuse them with the surface membrane. CD107a becomes detectable on the outside of the cell, providing a flow-cytometric readout of granule exocytosis.

Low CD107a mobilization can point toward defects involving granule docking, priming, or fusion, including disorders associated with UNC13D, STX11, STXBP2, and RAB27A. The pattern is not perfectly gene-specific, and clinical context remains essential. Some defects are partial, temperature-sensitive, treatment-modified, or apparent only in particular cell populations.

Perforin expression testing evaluates the major pore-forming protein encoded by PRF1. Absent or markedly reduced perforin in NK cells and cytotoxic T cells strongly supports a perforin-related disorder in the appropriate patient. Some disease-causing variants permit near-normal staining but impair protein function, so normal expression cannot eliminate every PRF1 abnormality.

Granzyme B, SAP, and XIAP testing may be added when the phenotype suggests related immune dysregulation. SAP deficiency is associated with X-linked lymphoproliferative disease and severe Epstein–Barr virus-related illness. XIAP deficiency can produce HLH, inflammatory bowel disease, and recurrent inflammation. These protein screens can rapidly focus genetic testing, particularly during acute illness.

For genetic HLH screening, perforin expression and CD107a degranulation have shown better sensitivity and at least similar specificity compared with traditional NK cytotoxicity in major clinical studies. They also provide more direct information about the step that may be defective. Traditional killing assays can still be useful for selected NK-cell deficiency questions or when the laboratory’s diagnostic pathway includes them.

The distinction between screening and diagnosis is important. Abnormal degranulation or protein expression supports a pathway defect, but sequencing and sometimes functional confirmation establish the molecular diagnosis. Conversely, treatment should not be withheld from a critically ill patient with a convincing HLH syndrome while specialized tests are pending.

Why the Test Is Ordered

One indication is a suspected inborn error of cytotoxic immunity. The clinical pattern may include disseminated or unusually severe herpes simplex, varicella-zoster, cytomegalovirus, or Epstein–Barr virus infection; extensive or persistent papillomavirus disease; recurrent viral complications; or a family history of early deaths, HLH, or immune deficiency. The function test helps determine whether normal-appearing NK cells can perform key tasks.

Another major indication is suspected HLH. Persistent fever, enlarged liver or spleen, cytopenias, very high or rapidly rising ferritin, liver injury, high triglycerides, low fibrinogen, neurologic symptoms, and organ dysfunction can prompt urgent evaluation. Current diagnostic workups favor targeted cytotoxic screens such as perforin and CD107a rather than relying solely on a general NK-killing result.

The test may also be used after an abnormal NK-cell count. Persistently very low NK numbers plus characteristic viral disease can suggest developmental NK-cell deficiency. A normal count with a strong phenotype raises the possibility of a functional defect. Testing should be selected by an immunologist because no one assay covers recognition, signaling, granule content, degranulation, and killing simultaneously.

Cancer and transplant programs sometimes evaluate NK function in research, treatment monitoring, or cellular-therapy development. These uses may employ highly specialized assays and are not directly interchangeable with clinical immune-deficiency testing. A study showing altered NK activity in a disease population does not mean the assay is validated to diagnose that disease in an individual.

NK activity tests are sometimes marketed for chronic fatigue, wellness, stress, infertility, recurrent miscarriage, or cancer screening. Evidence for using a nonspecific blood NK function result to diagnose these conditions or guide unproven immune treatments is limited. Uterine NK cells differ from circulating NK cells, and peripheral testing does not directly measure implantation-site behavior.

Testing is most valuable when the result will change the next step: urgent HLH genetics, antiviral planning, immune-deficiency evaluation, transplant decisions, or focused pathway analysis. It is less useful as a broad screen in a person without a compatible infection or hyperinflammation history.

Meaning of Low or Abnormal Results

A low cytotoxicity result means less target-cell death occurred than expected under the assay conditions. It does not identify the cause. The first questions are whether enough NK cells were present, whether the cells were viable, whether controls performed correctly, and whether the sample arrived within the laboratory’s time window.

Primary disorders can affect NK-cell development, receptor signaling, granule formation, perforin content, granule movement, membrane fusion, or post-degranulation killing. Some are relatively NK-cell selective; others affect CD8 T cells, platelets, pigmentation, neurologic function, bone marrow, or multiple immune compartments. The accompanying phenotype often points toward the pathway.

Secondary suppression is much more common. Acute viral or bacterial infection, sepsis, critical illness, malnutrition, malignancy, liver disease, autoimmune inflammation, chemotherapy, corticosteroids, calcineurin inhibitors, JAK inhibitors, and other treatments can reduce measured activity. Exhaustion after intense immune stimulation can also produce a temporary low response.

Low CD107a after stimulation suggests impaired degranulation, but technical failure, poor viability, inadequate stimulation, or too few gated NK cells can also lower the result. The laboratory’s positive-control response and unstimulated baseline are crucial. A report may be indeterminate rather than truly abnormal when the sample quality is poor.

Low or absent perforin expression is more specific for a perforin-pathway concern than low bulk killing, but it still requires genetic and clinical correlation. Normal perforin with low degranulation points toward a different step. Normal degranulation with poor killing can suggest defective granule contents, target recognition, or another downstream problem.

High activity is usually less diagnostically specific. It can reflect recent immune stimulation, cytokine exposure, a high proportion of activated NK cells, treatment effects, or assay variation. A high result does not establish autoimmunity, infertility, protection from cancer, or excessive immunity requiring suppression.

Borderline results deserve caution. Biological variability and assay imprecision are greatest near the reference boundary. Repeat testing with appropriate controls may be more informative than assigning a disease label to one mildly low value.

Specimen Timing, Medicines, and False Results

NK functional assays are living-cell tests. They require cells that can still recognize, signal, degranulate, and kill after collection. This makes preanalytic handling unusually important. Many laboratories require sodium heparin or another specified anticoagulant, a minimum blood volume, room-temperature transport, and delivery within a narrow number of hours.

Weekends and holidays matter because samples may not be processed promptly. Some laboratories schedule collection only on particular weekdays and require advance coordination with a healthy control. Freezing whole blood, refrigeration when not permitted, heat exposure, delayed flights, or vigorous temperature swings can reduce function even when the cells remain countable.

Acute illness complicates interpretation. A sample collected during severe infection or hyperinflammation may show secondary dysfunction that improves after recovery. In suspected HLH, however, testing is often necessarily performed during illness. The team interprets the result as part of the syndrome and uses genetic or repeated studies to distinguish inherited from acquired dysfunction.

Corticosteroids and other immunosuppressive drugs can lower activation and cytokine responses. Chemotherapy can reduce both NK number and quality. Recent transfusion, stem-cell transplantation, donor lymphocytes, or cellular therapy can create mixed-cell populations whose origin matters. The collection date should be linked to every relevant treatment.

The NK count should be measured near the functional sample. If few NK cells are present, low bulk killing may not represent poor function per cell. A differential count performed days earlier may not reflect the test tube used for function, particularly during rapidly changing illness.

Laboratory methods differ in target cells, incubation, effector preparation, stimulation, endpoint, and reference population. A numerical percentage from one method should not be trended against a different platform without understanding the change. “Normal” and “low” are assay-specific.

Failed controls invalidate interpretation. High spontaneous target death, weak positive-control activation, low patient-cell viability, or insufficient NK events can make the result uninterpretable. Repeating a compromised test is not unnecessary duplication; it may be the only way to obtain a biologically valid answer.

Interpretation and Follow-Up Testing

Begin with the exact assay. Determine whether the report measured target killing, CD107a mobilization, intracellular perforin, cytokine release, or another endpoint. The phrase “NK activity” alone is too vague. Check the stimulus, cell population, reference interval, viability, controls, and laboratory comments.

Then compare function with quantity. Review the absolute NK count and percentage, total lymphocyte count, CD3 T cells, CD4 and CD8 cells, and B cells. Low activity with a very low NK count has a different meaning from low activity in a sample with normal NK numbers.

Match the laboratory pattern to the clinical phenotype. For viral susceptibility, document the organism, severity, recurrence, tissue involvement, age at onset, treatment response, vaccine history, and family history. For suspected HLH, review ferritin trends, cytopenias, liver tests, triglycerides, fibrinogen, soluble CD25, organ enlargement, neurologic findings, and infection or malignancy triggers.

Follow-up may include repeat cytotoxicity under optimal transport conditions, CD107a degranulation, perforin and granzyme expression, SAP or XIAP protein testing, expanded NK phenotyping, antibody-dependent cytotoxicity, T-cell function, immunoglobulins, vaccine antibody responses, and viral polymerase chain reaction testing. The sequence should be chosen by the suspected mechanism rather than ordering every available assay.

Genetic testing may use a targeted HLH or immune-deficiency panel, rapid exome sequencing during critical illness, or broader genome-based testing. A negative panel does not eliminate all functional immune disorders because variants may be missed, new genes continue to be discovered, and some abnormalities are acquired.

Management is based on the disease, not the isolated laboratory number. Patients with active HLH may need immediate immune-directed therapy and treatment of the trigger. Those with recurrent viral infection may need antiviral prevention, vaccination planning, immunoglobulin assessment, or transplant consideration depending on the diagnosis. A mildly abnormal test without a compatible phenotype may require only confirmation and observation.

The final interpretation should state what failed and what remains uncertain. For example: NK numbers are normal, CD107a degranulation is repeatedly reduced with valid controls, perforin expression is preserved, and the clinical history supports a granule-release disorder. That statement is far more useful than “NK function low” because it directs confirmatory genetics and clinical decisions.

References

Disclaimer

This article is for general education and does not diagnose natural killer cell deficiency, HLH, infection, infertility, or cancer. NK functional tests require specialist interpretation with assay controls, specimen timing, medicines, cell counts, symptoms, and confirmatory immune or genetic studies. Severe infection, persistent fever with organ dysfunction, or suspected HLH requires urgent medical assessment.

RELATED ARTICLESMORE FROM AUTHOR